NNOX Nasdaq X-Ray Apparatus & Tubes & Related Irradiation Apparatus Financials FY2018βFY2025
Nano-X Imaging Ltd. had $13.0M of revenue in fiscal 2025, up 15.4% on the year before.
Hi! I read Nano-X Imaging Ltd.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
+15.4%
Yes. Sales grew 15.4% last year.
Does it make a profit?
β576.1%
No. It lost money last year.
Does profit turn into cash?
β345.6%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 9
Weak. It passes 3 of 9 health tests.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days Nano-X Imaging Ltd. did it, and the next one. Share prices often move a lot on those days.
Next results
November 19, 2026
Thursday Β· in 24 days
| Date | Results for | Time | Source |
|---|---|---|---|
| Apr 30, 2026 | Period ended Dec 31, 2025 | After the market closes | 20-F β |
| Apr 9, 2025 | Period ended Dec 31, 2024 | After the market closes | 20-F β |
| Apr 22, 2024 | Period ended Dec 31, 2023 | Before the market opens | 20-F β |
| May 1, 2023 | Period ended Dec 31, 2022 | Before the market opens | 20-F β |
| May 2, 2022 | Period ended Dec 31, 2021 | Before the market opens | 20-F β |
| Apr 6, 2021 | Period ended Dec 31, 2020 | After the market closes | 20-F β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· Nano-X Imaging Ltd. had $13.0M of revenue in fiscal 2025, up 15.4% on the year before. Its operating margin was β600.8%, down 97.9Β pts: of every 100 in sales, about β601 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Margins, % of revenue
KIRA Β· Nano-X Imaging Ltd. lost $75.0M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was β$45.0M in fiscal 2025, β345.6% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
KIRA Β· Nano-X Imaging Ltd. has $46.0M more cash than debt.
Cash, debt and the ratios that show how comfortably Nano-X Imaging Ltd. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $88.7M | $77.6M | $82.4M | $57.7M | $49.2M |
| Debt incl. finance leases | $0.1M | $3.5M | $3.5M | $6.1M | $3.1M |
| Debt / equity | 0.0x | 0.0x | 0.0x | 0.0x | 0.0x |
| Current ratio | 1.8x | 3.3x | 5.7x | 5.6x | 4.0x |
| Quick ratio | 1.8x | 3.3x | 5.6x | 5.5x | 3.8x |
| Total assets | $363M | $254M | $219M | $210M | $162M |
| Total liabilities | $71.0M | $37.3M | $23.1M | $20.9M | $22.4M |
| Shareholders' equity | $292M | $217M | $196M | $189M | $140M |
| Net debt (β = net cash) | β$88.6M | β$74.1M | β$78.9M | β$51.6M | β$46.0M |
KIRA Β· Its return on capital was β65.9%: every 100 invested in the business earned about β66 in a year.
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Nano-X Imaging Ltd. passes 3 of 9 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β |
| F-score | β / 3 | β / 4 | β / 6 | β / 5 | 4 / 8 | 6 / 9 | 3 / 9 | 3 / 9 |
| Accruals ratio | β | β143.5% | β17.9% | β7.9% | β22.6% | β6.8% | β7.9% | β18.4% |
| Altman Z'' | β | β30.25 | 48.41 | 2.63 | 1.14 | 4.37 | 3.91 | β3.70 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | β | β | β | $1.3M | $8.6M | $9.9M | $11.3M | $13.0M |
| Gross profit | β | β | β | β$1.5M | β$6.9M | β$6.6M | β$10.6M | β$12.8M |
| Research and development | $0.7M | $2.7M | $9.2M | $17.1M | $26.5M | $26.0M | $20.2M | $19.2M |
| Operating income | β$1.9M | β$22.6M | β$43.9M | β$61.6M | β$118M | β$62.6M | β$56.7M | β$78.2M |
| Pretax income | β | β$22.6M | β$43.8M | β$61.8M | β$117M | β$61.1M | β$53.9M | β$76.8M |
| Income tax | β | β | β | β$0.0M | β$3.7M | β$0.3M | β$0.4M | β$1.8M |
| Net income | β$1.9M | β$22.6M | β$43.8M | β$61.8M | β$113M | β$60.8M | β$53.5M | β$75.0M |
| Net income to common | β | $22.6M | $43.8M | $61.8M | $113M | β | β | β |
| Diluted EPS | β$0.09 | β$0.90 | β$1.23 | β$1.28 | β$2.17 | β$1.08 | β$0.91 | β$1.16 |
| Diluted shares | 0.02B | 0.03B | 0.04B | β | 0.05B | 0.00B | 0.00B | 0.00B |
| Cash flow | ||||||||
| Cash from operations | β$3.7M | β$5.5M | β$21.6M | β$38.1M | β$43.4M | β$44.8M | β$36.6M | β$40.8M |
| Capital expenditure | $0.1M | $0.1M | $13.9M | $23.2M | $7.2M | $3.3M | $2.8M | $4.2M |
| Free cash flow | β$3.7M | β$5.6M | β$35.5M | β$61.2M | β$50.6M | β$48.1M | β$39.4M | β$45.0M |
| Depreciation and amortization | $0.0M | $0.1M | $0.2M | $0.5M | $0.9M | $1.2M | $1.1M | $1.2M |
| Stock-based compensation | $0.1M | $16.2M | $24.8M | $18.8M | $18.6M | $6.8M | $7.3M | $4.2M |
| Acquisitions | β | β | β | $2.9M | β | β | β | $0.2M |
| Balance sheet | ||||||||
| Cash and short-term investments | $0.0M | $8.1M | $213M | $88.7M | $77.6M | $82.4M | $57.7M | $49.2M |
| Total debt | β | β | β | $0.1M | $3.5M | $3.5M | $6.1M | $3.1M |
| Current assets | β | $9.6M | $220M | $94.9M | $82.5M | $88.6M | $78.7M | $66.8M |
| Current liabilities | β | $20.3M | $4.5M | $52.8M | $25.1M | $15.5M | $14.0M | $16.9M |
| Inventory | β | β | β | $0.1M | β | $2.4M | $1.5M | $3.1M |
| Property and equipment, net | β | $0.2M | $14.0M | $37.4M | $43.5M | $42.3M | $45.4M | $29.7M |
| Goodwill | β | β | β | $58.3M | $7.4M | β | β | $0.3M |
| Intangible assets | β | β | β | $102M | $91.2M | $80.6M | $70.0M | $59.9M |
| Total assets | β | $11.9M | $236M | $363M | $254M | $219M | $210M | $162M |
| Total liabilities | β | $20.6M | $5.4M | $71.0M | $37.3M | $23.1M | $20.9M | $22.4M |
| Shareholders' equity | β$6.4M | β$8.8M | $231M | $292M | $217M | $196M | $189M | $140M |
| Margins | ||||||||
| Gross margin | β | β | β | β116.0% | β80.2% | β66.6% | β94.0% | β98.2% |
| Operating margin | β | β | β | β4,720.7% | β1,372.2% | β631.9% | β502.9% | β600.8% |
| EBITDA margin | β | β | β | β4,680.5% | β1,361.7% | β619.8% | β493.0% | β591.7% |
| Net margin | β | β | β | β4,739.1% | β1,320.2% | β613.6% | β474.3% | β576.1% |
| FCF margin | β | β | β | β4,694.7% | β589.4% | β485.4% | β348.9% | β345.6% |
| Returns | ||||||||
| Return on capital | β | β | β | β23.9% | β65.2% | β42.4% | β32.6% | β65.9% |
| Return on capital employed | β | 269.0% | β19.0% | β19.8% | β51.4% | β30.8% | β28.9% | β53.9% |
| Return on equity | β | β | β39.5% | β23.6% | β44.5% | β29.5% | β27.8% | β45.6% |
| Return on assets | β | β190.1% | β35.3% | β20.6% | β36.7% | β25.7% | β25.0% | β40.3% |
| Return on tangible equity | β | β | 19.0% | 46.8% | 95.9% | β52.9% | β44.9% | β94.3% |
| Growth | ||||||||
| Revenue growth | β | β | β | β | 557.8% | 15.5% | 13.9% | 15.4% |
| Share count change | β | 21.1% | 41.6% | β | β | β99.9% | 4.1% | 10.4% |
| Financial health | ||||||||
| Debt / equity | β | β | β | 0.0x | 0.0x | 0.0x | 0.0x | 0.0x |
| Current ratio | β | 0.5x | 49.1x | 1.8x | 3.3x | 5.7x | 5.6x | 4.0x |
| Quick ratio | β | 0.5x | 49.1x | 1.8x | 3.3x | 5.6x | 5.5x | 3.8x |
| Capital allocation | ||||||||
| Capex / revenue | β | β | β | 1,775.9% | 83.6% | 33.3% | 24.5% | 32.3% |
| Stock comp / revenue | β | β | β | 1,442.2% | 217.1% | 69.0% | 64.4% | 32.2% |
| Quality scores | ||||||||
| Piotroski F-score | β | β | β | β | 4.0 | 6.0 | 3.0 | 3.0 |
| Altman Z'' | β | β30.2 | 48.4 | 2.6 | 1.1 | 4.4 | 3.9 | β3.7 |
| Accruals ratio | β | β143.5% | β17.9% | β7.9% | β22.6% | β6.8% | β7.9% | β18.4% |
Source: SEC EDGAR XBRL filings (CIK 0001795251). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
